Nahum Ferera

About Nahum Ferera

“My work has focused on advancing EyeYon Medical’s EndoArt through a decisive phase of global clinical and regulatory execution, culminating a journey that began more than 15 years ago. That journey was shaped by repeated encounters with patients whose lives were defined by blurred vision, long waiting times for donor tissue, and limited therapeutic options. Together with Ofer Daphna, we believed that corneal edema should not inevitably lead to transplantation or irreversible visual loss. For many years, this vision existed only as an idea, questioned, delayed, and constrained by the realities of science, regulation, and clinical skepticism. Perseverance, collaboration, and an unwavering commitment to patients ultimately carried it forward.

“In the last 12 months, that vision has begun to materialize in a way that is both humbling and profoundly rewarding. Through EndoArt, we are now witnessing corneal healing and visual improvement in patients who once had little hope beyond transplantation.

“This progress is reflected in concrete milestones. EndoArt has been successfully launched in the EU with growing clinical adoption. Enrollment in the China clinical study has been completed, opening the path to one of the world’s largest underserved populations. In parallel, we are actively preparing for a U.S. FDA pivotal trial, positioning EndoArt for global scale.

“Collectively, these achievements signal the emergence of a new therapeutic paradigm. By shifting corneal care from tissue replacement to functional restoration, EndoArt has the potential to reduce reliance on donor tissue and expand access to care.”